autologous mesenchymal stem cells / Mayo Clinic, National Institute of Neurological Disorders and Stroke - LARVOL DELTA

Mesenchymal Stem Cell Therapy in Multiple System Atrophy (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Mar 2025 ➔ Mar 2026 | Trial primary completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Multiple System Atrophy

Angiographic Delivery of AD-MSC for Ulcerative Colitis (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Angiographic Delivery of AD-MSC for Ulcerative Colitis (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

The impact of hypoxia preconditioning on mesenchymal stem cells performance in hypertensive kidney disease. (PubMed, Stem Cell Res Ther) - "HPC has a more favorable functional effect on HC- than on HKD-MSC, reflected in increased proliferation and EGF release, and modest decrease in senescence, whereas it has little effect on HTN or HKD MSCs."

Journal • Nephrology • Renal Disease

Mesenchymal Stem Cell Therapy in Multiple System Atrophy (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Mar 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Multiple System Atrophy

Allogeneic Mesenchymal Stem Cells After In Vivo Transplantation: A Review. (PubMed, Cell Reprogram) - "Autologous mesenchymal stem cells (MSCs) are ideal for tissue regeneration because of their ability to circumvent host rejection, but their procurement and processing present logistical and time-sensitive challenges...Extensive research has been conducted in the treatment of autoimmune, degenerative, and inflammatory diseases with such stem cells, and has demonstrated predominantly safe outcomes with minimal complications. Nevertheless, continued clinical trials are necessary to ascertain optimal harvest and transplant techniques."

Journal • Preclinical • Review • Immunology • Inflammation • Transplantation

Angiographic Delivery of AD-MSC for Ulcerative Colitis (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Safety of Allogeneic Mesenchymal Stem Cell Seeding of NeuraGen® Nerve Guides in a Rabbit Model. (PubMed, Tissue Eng Part C Methods) - "Impact statement Autologous mesenchymal stem cells (MSC) have been reported to enhance nerve regeneration when used in conjunction with nerve graft substitutes...When compared to unseeded nerve conduits, allogeneic MSC-seeded conduits did not induce a systemic or local immune response. The findings of this study will ultimately facilitate the."

Journal • Preclinical • Hematological Disorders • CD4 • CD8

Durable Response Seen in Patients With Refractory Fistulizing Perianal Crohn's Disease Using Autologous Mesenchymal Stem Cells on a Dissolvable Matrix: Results from the Phase I Stem Cell on Matrix Plug (STOMP) Trial. (PubMed, Dis Colon Rectum) - "A stem cell-loaded plug can safely and effectively deliver cell-based therapy for patients with single tract fistulizing perianal Crohn's disease. See Video Abstract at http://links.lww.com/DCR/C70."

Journal • P1 data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease

Angiographic Delivery of AD-MSC for Ulcerative Colitis (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis